Laboratoires Thea — Sponsor Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

Open in Search →

8 Registered trials

3 Recruiting

2 Completed trials

10 Countries active

9 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 2 Phase II: 5 Phase IV: 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Retinitis pigmentosa 2 Leber's congenital amaurosis 1 Vernal keratoconjunctivitis 1 Periodontitis 1 Myopia 1

Top IMPs

ULTEVURSEN 2 CICLOSPORIN 1 COLECALCIFEROL 1 FENOFIBRATE, ROSUVASTATIN 1 NACYSTELYN 1 PRAVASTATIN SODIUM, FENOFIBRATE 1 SEPOFARSEN 1 SODIUM PHENYLBUTYRATE 1 TACROLIMUS MONOHYDRATE 1

All trials

8 total

A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with… Not authorised

2024-515199-10-00 Phase II 4 countries ULTEVURSEN
Safety and efficacy of T10430 eye drops in controlling paediatric myopia progression Pending

2025-521563-13-01 Phase II 1 country SODIUM PHENYLBUTYRATE
A Study to Compare the Effectiveness and Safety of T1695 (0.1% Tacrolimus) Versus Ciclosporin in Participants With Moderate to Severe Vernal… Pending

2025-521567-12-00 Phase II 5 countries CICLOSPORIN; TACROLIMUS MONOHYDRATE
A Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects with Retiniti… Recruiting

2024-515199-10-01 Phase II 6 countries ULTEVURSEN
A Double-Masked, Randomized, Placebo-Controlled, Paired Eye Study to Evaluate the Efficacy, Safety and Tolerability of Sepofarsen in Subject… Recruiting

2024-518378-14-00 Phase III 5 countries SEPOFARSEN
Study to compare the efficacy and safety of a 12-week administration of two fixed-dose combinations (Rosuvastatin 20 mg and Fenofibrate 160 … Recruiting

2024-514289-38-00 Phase III 1 country FENOFIBRATE, ROSUVASTATIN; PRAVASTATIN SODIUM, FENOFIBRATE
Effect of Vitamin D supplementation in participants with periodontitis and vitamin D deficiency. Ended

2023-503671-16-00 Phase IV 1 country COLECALCIFEROL
Effect of NAL in participants with sleep disorders Ended

2023-508445-40-00 Phase II 2 countries NACYSTELYN

Showing 1–8 of 8 trials

← All sponsors A–Z